Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach?
Notch signalling may be a future therapeutic target for the treatment of advanced pcALCL.
There was no active control condition (e.g., treatment waitlist) for comparison of treatment effects.